secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0000939767-24-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q4 2023 revenue $479.7M, GAAP EPS $0.27, non-GAAP $0.33; FY revenue $1.83B
--------------------------------------------------------------------------------

- Total Q4 revenues $479.7M (up from $423.9M YoY); cabozantinib net product revenues $429.3M.
- GAAP diluted EPS $0.27 (Q4) and $0.65 (FY); non-GAAP diluted EPS $0.33 (Q4) and $0.90 (FY).
- FY 2023 total revenues $1.83B, up 14% from $1.61B; net product revenues $1.63B.
- R&D expenses $244.7M (Q4) vs $336.8M YoY; SG&A $131.4M vs $119.3M YoY.
- Pipeline: regulatory strategies for cabozantinib label expansions; MSN IP litigation ruling expected spring 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000025/0000939767-24-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000025/exel-20240206.htm
  HTML page:      https://secwatch.observer/filing/0000939767-24-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer